Key result
Pharmacological management of cardiorenal syndromes is complicated by organ interactions, necessitating a thorough understanding of pathophysiology and high-quality future studies.
This review highlights the complex interplay between heart and kidney dysfunction and outlines current pharmacological strategies for managing cardiorenal syndromes.
Answers are grounded in this paper and cite their sources.
Requires integrated cardiorenal assessment before therapy; leaves open optimal regimens pending high-quality trials.
Cardiorenal syndromes are disorders of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. The pharmacological management of Cardiorenal syndromes may be complicated by unanticipated or unintended effects of agents targeting one organ on the other. Hence, a thorough understanding of the pathophysiology of these disorders is paramount. The treatment of cardiovascular diseases and risk factors may affect renal function and modify the progression of renal injury. Likewise, management of renal disease and associated complications can influence heart function or influence cardiovascular risk. In this paper, an overview of pharmacological management of acute and chronic Cardiorenal Syndromes is presented, and the need for high-quality future studies in this field is highlighted.
No takes yet. Share an insight, caveat, or question.
House et al. (2011) conducted a review in Cardiorenal Syndromes. Pharmacological management was evaluated. Pharmacological management of cardiorenal syndromes is complicated by organ interactions, necessitating a thorough understanding of pathophysiology and high-quality future studies.
Synapse has enriched 10 related papers. Consider them for comparative context: